Investor Registration
Join Global Life Science Investors
Over 250+ investors converge in Boston to shape the future of biotech, pharmatech and medtech investment.
Qualified Investor* passes are discounted to $595 until 29 August 2025. Please check qualifying T&Cs below before you register.
Why Leading Investors Choose LSX USA
"LSX USA Congress is very much your event as an investor, it was conceived, produced and executed with investors wholly in mind - 80% of our audience comes from our key core profiles, so that's C-suite of innovators, other investors, global heads of BD and pharma [...] allowing you to maximise your time with the right people." - Matt Pullan, Managing Director of LSX USA Congress
- Expand your network and connect with 250+ investors and 1000+ senior attendees
- Leverage the partneringONE platform designed specifically for investors to find ideal and high-quality matches
- Gain access to exclusive networking with fellow investors
- Hear from top industry leaders with our tailored presentation streams in biotech, medtech and pharmatech.
"LSX knows its audience, investors, strategic partners and start ups. They do a great job of meeting their needs." - Maria Shepherd, President, Medi-Vantage LLC
Qualified Investors and Complimentary Passes
Qualified Investors* can receive complimentary registration to LSX USA Congress with our Engaged Investor Pass.
An investor who receives complimentary registration is expected to participate in the One-on-One Partnering, with at least five meetings secured through our networking tool, partneringONE, with life science companies.
Contact Elsie Fell at elsie@lsxleaders.com for more information and to receive your complimentary pass.
*Qualified Investors include:
- Senior management or investment staff with a Fund (ETF, mutual fund, or other non- bank institution) currently invested in life sciences.
- Senior management or investment staff from a pension or employee benefit plan currently invested in life sciences.
- Senior management at a family office currently or previously invested in life sciences.
- Senior leadership or management with a venture or private equity firm managing assets of $25 million or more.
- Senior management at an angel investor fund (or group) currently or previously invested in life sciences. Not individual Angels.
- Senior management at a charitable or not-for-profit organization with a fund of $5 million or more currently invested in the life sciences.
- Research Analyst for a fund currently invested in UK/EU/US/Asian life science companies.
Attendees who do not qualify for complimentary registration include:
- Executives who invest personal, disposable income, who's salaried occupation is not that of a full time investor (i.e. not individual Angels)
- Firms who offer advisory or consulting services of any nature.
- Firms who offer brokerage services of any nature.
- Crowd funding platforms.
- Service providers/consultants to the biotech industry.
- Biotech/ life sciences company employee or product suppliers to the biotech industry including CRO’s and CMO’s.
- Firms that provide services and/or charge a fee to biotech companies in exchange for research/media/investor relations coverage.
- Retail/individual investors.
- Investment and merchant bankers.
- Real estate development professionals.
- Members of economic development organisations.
- Firms who have a service providing component to their fund’s business model will be evaluated on a case by case basis. If this fund’s information is NOT located in any mainstream database (Ipreo, FactSet), LSX may ask for references for investor qualification.
LSX reserves the right, in its sole discretion, to make the determination of the proper classification of an investor or registrant.
LSX reserves the right to publish materials and restrict conference and/or partnering system access consistent with these determinations.
If you have any questions please contact Elsie Fell at elsie@lsxleaders.com
Hear from LSX USA's Managing Director, Matt Pullan
Matt shares what's to come for this year's event, ways investors can maximise their time, access tailored content and what sets LSX apart from the rest as a leading event for life science investments.
